Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2007

View Archived Issues

Minodronate effective in Japanese women with postmenopausal osteoporosis

Symphony GenIsis acquired by Isis

Patient enrollment completed in Barrier's pivotal phase III trial of Hyphanox

Osteopontin: a novel target for the treatment of uveoretinitis

Local delivery of VIP-loaded liposomes effectively protects ocular tissue in rats with EAU

Preclinical efficacy, pharmacokinetics and safety of the ETB agonist SPI-1620

Actelion begins phase IIa proof-of-concept study of Zavesca for CF

First patients enrolled in Transgene's phase I trial of HCV vaccine TG-4040

Recordati to acquire Orphan Europe

Positive results for Diffusion's phase I safety trial of TSC

BioLineRx in-licenses novel peptide for cancer

Phase II studies commence for PYY3-36 nasal spray to treat obesity

RDEA-119 enters human clinical trials in advanced cancer patients

Merck & Co. donates cervical cancer vaccine Gardasil in lowest income nations

Nemonoxacin's preclinical profile reported

AR-2474: a novel topical antibiotic against MRSA infections

Novel contraceptive agents imparted by Pharmacopeia

Recent Ferring patent reports novel agents for use in critical care medicine

Taxotere receives FDA approval for expanded SCCHN indication

Novel immunosuppressant agents disclosed in recent Synta patent

Oncolytics Biotech reports positive interim data from combination Reolysin/radiation trial

Sublinox shows promise in comparative study for sleep disturbances

Novel antihypertensive agents prepared and tested at Torrent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...